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Background: As proinflammatory cytokines seem to play a role in discogenic back pain, substances exhibiting
anti-inflammatory effects on intervertebral disc cells may be used as minimal-invasive therapeutics for intradiscal/
epidural injection. The purpose of this study was to investigate the anti-inflammatory and anti-catabolic potential of
curcuma, which has been used in the Indian Ayurvedic medicine to treat multiple ailments for a long time.
Methods: Human disc cells were treated with IL-1β to induce an inflammatory/catabolic cascade. Different extracts of
curcuma as well as curcumin (= a component selected based on results with curcuma extracts and HPLC/MS analysis)
were tested for their ability to reduce mRNA expression of proinflammatory cytokines and matrix degrading enzymes
after 6 hours (real-time RT-PCR), followed by analysis of typical inflammatory signaling mechanisms such as NF-κB
(Western Blot, Transcription Factor Assay), MAP kinases (Western Blot) and Toll-like receptors (real-time RT-PCR).
Quantitative data was statistically analyzed using a Mann Whitney U test with a significance level of p< 0.05 (two-tailed).
Results: Results indicate that the curcuma DMSO extract significantly reduced levels of IL-6, MMP1, MMP3 and MMP13.
The DMSO-soluble component curcumin, whose occurrence within the DMSO extract was verified by
HPLC/MS, reduced levels of IL-1β, IL-6, IL-8, MMP1, MMP3 and MMP13 and both caused an up-regulation of TNF-α.
Pathway analysis indicated that curcumin did not show involvement of NF-κB, but down-regulated TLR2 expression and
inhibited the MAP kinase JNK while activating p38 and ERK.
Conclusions: Based on its anti-inflammatory and anti-catabolic effects, intradiscal injection of curcumin may be an
attractive treatment alternative. However, whether the anti-inflammatory properties in vitro lead to analgesia in vivo will
need to be confirmed in an appropriate animal model.
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Degeneration of the intervertebral disc is characterized
by enhanced proteolytic degradation of extracellular
matrix proteins as well as altered matrix protein synthe-
sis. This overall catabolic shift leads to changes in the tis-
sue structure that have been extensively described in the
literature [1-7]. Although large structural changes can be
observed during degeneration, this age-related process
does not necessarily cause pain symptoms.
There is certain evidence in the literature that in a
subgroup of patients, painful disc degeneration is
characterized by increased levels of proinflammatory
cytokines, e.g. interleukin 1β (IL-1β), interleukin 6
(IL-6), interleukin 8 (IL-8) and tumor necrosis factor
α (TNF-α) [6,8-11]. Although proinflammatory med-
iators seem to play a crucial role in intervertebral
disc diseases, little is known about inflammatory
pathways in intervertebral disc cells. Results from
studies on the pathogenesis of cartilage degeneration
indicate that proinflammatory processes are mostly
regulated by the transcription factor NF-κB [12],
whose activity is tightly regulated in vivo, e.g. by ac-
tivation of the so-called Toll-like receptors (TLRs)
[13]. Another important inflammatory pathway is the
MAP kinase pathway that consists of a family of pro-
tein kinases with the major members being p38, ERK
and JNK [14,15]. Due to the lack of knowledge con-
cerning the molecular events underlying discogenic
back pain, treatment of painful disc disease is cur-
rently limited, with typical options for the patient
being conservative treatment (e.g. physiotherapy) and
oral pain medication, both of which often only have
a temporary effect. Other options are various types
of surgical interventions, but these lead to high risks
for the patients and high costs for the health care
systems. Therefore, research in the most recent past
has concentrated on the development of minimal-in-
vasive, yet effective new treatment options, covering
approaches from cell and gene therapy to anti-
inflammatory substances for intradiscal injection.
Currently, corticosteroidal substances are frequently
used, which are known to have a significant risk for
side effects and may cause disc space infections [16].
Although research on biodrugs with regard to spinal
diseases is yet rare, these novel anti-inflammatory
candidates could potentially benefit patients with dis-
cogenic back pain.
Curcuma (Curcuma longa L., Zingiberaceae) is a per-
ennial herb that is cultivated in Asian countries. As a
powder, it has not only been used for cooking for centur-
ies, but also as a drug in the traditional Chinese and
Indian medicine, treating e.g. diabetic wounds, hepatic
disorders, rheumatism and sinusitis [17]. Numerous pub-
lications demonstrated an anti-inflammatory effect ofcurcuma, with its effect probably being related to a class
of substances called curcuminoids [18].
Based on a thorough literature review, we hypothesize
that curcuma has the potential to interfere with catabolic
and inflammatory pathways. Hence, the aim of this study
was to analyze the effects of curcuma extracts as well as
of one selected component of curcuma on IL-1β
mediated cellular responses of human intervertebral disc
cells in vitro. Additionally, its mechanism of action was
investigated by testing for involvement of NF-κB, MAP
kinases (i.e. p38, ERK, JNK) and TLR2.Methods
General experimental design
As an inflammatory environment is thought to be
present in (a subgroup of) patients with discogenic back
pain, human intervertebral disc cells (cultured in 2D)
were pretreated with recombinant IL-1β, thus increasing
the levels of proinflammatory cytokines and matrix de-
grading enzymes. Thereafter, different solvents (DMSO,
ethanol) were used to prepare sequential curcuma
extracts and tested for their ability to reduce inflamma-
tory and catabolic gene expression after 6 hours. The
presumably most abundant bioactive substance in the
most potent extract was chosen based on structure-
based solubility, information in the literature and identi-
fication using HPLC/MS analysis (i.e. curcumin) and
tested in the same setting, using various concentrations.
A mechanistic investigation, looking at involvement of
the NF-κB, MAP kinase and TLR2 pathway, was per-
formed for curcumin as well.Human intervertebral disc cell culture
Human intervertebral disc tissue (nucleus pulposus and
annulus fibrosus) was removed from 27 patients under-
going spinal surgery for discectomy or interbody fusion
for degenerative disc disease or disc herniation (for
detailed information see Table 1). Informed consent was
obtained from all patients prior to surgery in accordance
with the institutional review board.
Intervertebral disc cells were released from the tissue
by enzymatic digestion with 0.2% collagenase NB4
(Serva, Germany) and 0.3% dispase II (Roche Diagnos-
tics, Switzerland) in PBS (37°C, 5% CO2) for approxi-
mately 4 hours. After digestion, the tissue suspension
was filtered (70 μm cell strainer, BD Biosciences, Belgium),
washed and cells were seeded and expanded in DMEM/
F12 (Sigma, Switzerland) supplemented with 10% FCS,
penicillin (50 units/ml), streptomycin (50 μg/ml) and
ampicillin (125 ng/ml) (all Invitrogen, Germany), with
medium changes once to twice a week and expansion
up to passage 2 or 3.
Table 1 Demographic data on surgical disc samples
(M=male; F = female)
Nr. Sex Age Level Pathology Grade Experiments
1 F 15 L5/S1 Herniation 4 G
2 M 35 L4/5 Herniation 4 G
3 M 46 L3/4 Herniation 3 G
4 M 60 L4/5 Herniation 4 G
5 F 56 L1/2 Herniation 5 G
6 F 48 L4/5 Herniation 4 G
7 M 59 L5/S1 DDD 4 G
8 M 39 L4/5 Herniation 3 G
9 M 60 L4/5 Herniation 3 G
10 F 51 L4/5 DDD 4 G
11 F 48 L4/5 DDD 3 G
12 M 59 L5/S1 Herniation 3 G
13 F 42 L4/5 Herniation 4 G
14 M 28 L5/S1 Herniation 3 V
15 F 71 L1/2 Herniation 5 V
16 F 46 L5/S1 Herniation 5 V
17 M 61 L4/5 Herniation 3 V
18 F 59 L4/5 Herniation 3 V
19 M 57 L4/5 Herniation 4 P
20 M 48 L4/5 Herniation 3 P
21 F 23 L5/S1 Herniation 3 P
22 F 43 L4/5 Herniation 4 P
23 M 49 L5/S1 Herniation 4 P
24 F 50 L5/S1 Herniation 3 P
25 F 45 L5/S1 Herniation 4 P
26 F 40 L4/5 Herniation 4 P
27 N 26 L4/5 Herniation 4 P
Grade = Pfirrmann Grading; Pathology: DDD=Degenerative disc disease
Experiments: V = Viability, G =Gene expression analysis, P = Pathway analysis.
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Organic curcuma from McCormick (Promena, Switzerland)
was used to prepare sequential DMSO and ethanol extracts.
Briefly, curcuma was dispersed in DMSO at a concentra-
tion of 320 mg/ml, incubated on the shaker at room
temperature for 10 min and centrifuged at 2000 rpm for
10 min before taking off the DMSO fraction. The
remaining pellet was then dispersed in 100% ethanol and
the procedure was repeated. After removal of the ethanol
fraction, the thereafter remaining pellet was discarded. For
each experiment, the fractions were prepared freshly in
order to avoid any damage due to freezing/thawing.
HPLC/MS analysis of the curcuma DMSO and EtOH
extracts
The DMSO and EtOH extracts of curcuma were analysed
by high performance liquid chromatography (1200 SeriesHPLC, Agilent), coupled to a mass spectrometer (6130
series MS, Agilent). The chromatography of the curcuma
extracts was performed according to Wichitnithad et al.
[19], using a RP-C18 column (Agilent Eclipse Plus,
100 mm×2.1 mm i.d., 1.8 μm). For identification of the
curcuminoids, measurements were carried out with a
multimode source (electrospray (ESI) ionization mode:
positive mode; drying gas flow: 12 l/min; drying gas
temperature: 350°C; nebulizer pressure: 50 psig; fragmentor
voltage: 70 V; capillary voltage: 4000 V). The quantification
of the most abundant curcuminoids was done at a wave-
length of 425 nm, with commercially available curcumin
(Sigma Aldrich) as an external standard.
Viability measurement
Cells seeded in 24 well plates were treated with different
concentrations of curcuma DMSO extract (25, 50, 100,
250, 500 or 1000 μg/ml), curcuma ethanol extract
(25, 50, 100, 250, 500 or 1000 μg/ml) or curcumin (1, 5,
10, 20, 50 or 100 μM - dissolved in DMSO). All experi-
ments were performed in triplicates on cells from 5 inde-
pendent biopsies. After 6, 18 and 30 hours, toxicity was
analyzed using the MTT assay: A fresh sterile solution of
MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide] (Sigma, Switzerland) with a concentration
of 0.5 mg/ml in DMEM/F12 was prepared, 500 μl were
added to each well and incubated for 4 hours at 37°C.
MTT was discarded, cells were lysed with DMSO for
5 min at 37°C and absorbance was measured at 565 nm.
Absorbance of treated cells was calculated relative to ab-
sorbance of untreated control cells, which was set to 100%
(only changes in viability of >10% were considered). Con-
centrations that were non-toxic even at late time points
were chosen for subsequent experiments. Results of the
MTT assay were previously shown to be comparable to
other viability measurement techniques (DNA content by
Picogreen assay; cell counting) [20].
Gene expression analysis
Human intervertebral disc cells were serum starved for 2
hours and then exposed to 5 ng/ml IL-1β (Peprotech,
Great Britain) for 2 hours before adding 100 μg/ml cur-
cuma DMSO extract or 100 μg/ml curcuma EtOH
extract for 6 hours. Untreated control cells were included
to verify the inflammatory and catabolic response
induced by IL-1β treatment. As we were able to show
that the solvents did not influence cellular behavior (see
Additional file 1: Figure S1 and Additional file 2:
Figure S2), all groups were treated with the respective
volume (0.03%) of either DMSO or EtOH in all experi-
ments. Therefore, changes in gene expression are either
calculated relative to controls (+0.03% DMSO or EtOH)
or relative to IL-1β prestimulated cells (+0.03% DMSO
or EtOH). Based on the results with curcuma extracts
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solution of curcumin (which is one of the major DMSO-
soluble, bioactive components of curcuma) was prepared
and cells were treated with final concentrations of 5, 10
or 20 μM curcumin for 6 hours after IL-1β prestimula-
tion. Taking the approximate percentage of curcumin in
curcuma powder (~2%) into account, the applied range
of curcumin (5–20 μM) was predicted to be similar to
the final concentration of curcumin when using the
above mentioned curcuma extracts (100 μg/ml). All gene
expression experiments were performed on cells from
five independent biopsies.
After treatment, cells were harvested by trypsin treat-
ment and total RNA was isolated using the PureLink RNA
Mini Kit (Ambion, Switzerland) according to the manufac-
turer’s instructions. cDNA was synthesized using TaqMan
Reverse Transcription Reagents (Applied Biosystems,
Switzerland) and gene expression of IL-1β, IL-6, IL-8,
TNF-α, MMP1, MMP3, MMP13, TLR2 and TBP (TATA
box binding protein=housekeeping gene) was analyzed.
Human specific probes and primers (Applied Biosystems,
Switzerland, see Table 2), TaqMan real-time RT-PCR Mix
(Applied Biosystems, Switzerland) and 10–30 ng of cDNA
(depending on the expression level of the respective gene)
were mixed and measured in duplicates using the StepOne
Plus Real-Time PCR System (Applied Biosystems,
Switzerland). The comparative ct method (= 2-ΔΔCt
method) [21] was used to quantify PCR data. In order to
calculate changes in gene expression induced by curcuma/
curcumin, gene expression in IL-1β-treated cells was set to
100% and gene expression of IL-1β/curcuma or IL-1β-/
curcumin-treated cells was calculated relative to IL-1β-
treated cells (containing the respective amount of either
DMSO or EtOH as well).
Western Blot for NF-κB (p65)
In order to investigate whether changes in NF-κB/p65
translocation occur after treatment with curcuminTable 2 Primers/Probes used for real-time RT-PCR
(TaqManW Gene Expression Assays, Applied Biosystems)
Gene Primer sequence
number
Base
pairs
Interleukin-1β (IL-1β) Hs00174097_m1 94
Interleukin-6 (IL-6) Hs00174131_m1 95
Interleukin-8 (IL-8) Hs00174103_m1 101
Matrixmetalloproteinase-1 (MMP1) Hs00233958_m1 133
Matrixmetalloproteinase-3 (MMP3) Hs00968308_m1 98
Matrixmetalloproteinase-13 (MMP13) Hs00233992_m1 91
TATA box binding protein (TBP) Hs00427620_m1 91
Toll-like receptor 2 (TLR2) Hs00152932_m1 80
Tumor necrosis factor alpha (TNF-α) Hs00174128_m1 80
Data was obtained by real-time RT-PCR (ΔΔct method) (n = 10).(substance with most prominent effects, see results), disc
cell cultures were either kept untreated, treated with
5 ng/ml IL-1β alone or co-treated with 20 μM curcumin
for 60 min.
Nuclear extracts were prepared by washing trypsin-
harvested cells with 10 mM HEPES (pH 7.9), containing
1.5 mM MgCl2, 10 mM KCl, 1 mM PMSF, 5 mM DTT
and 0.1% protease inhibitors (pepstatin-A, leupeptin and
bestatin). Then, cells were lysed with 0.1% NP-40 for
5 min, centrifuged for 5 min at 10’000 rpm (4°C) and
supernatants were discarded. Nuclear pellets were
washed with 0.1% NP-40 and lysed for 20 min with
20 mM HEPES (pH 7.9), containing 1.5 mM MgCl2,
420 mM NaCl, 25% glycerol, 1 mM PMSF and 5 mM
DTT as well as protease inhibitors (see above). After cen-
trifugation, protein content was measured by Bradford
assay (Bio-rad, Germany).
Nuclear extracts of untreated, IL-1β-treated and IL-1β/
curcumin-treated cells were separated on a SDS-
polyacrylamid gel and transferred to a PVDF membrane
(Amersham, Switzerland). The membrane was incubated
with a p65 antibody (Santa Cruz, Germany) followed by
incubation with an appropriate HRP secondary antibody
before analyzing chemiluminescence. PARP (Poly [ADP-
ribose] polymerase) was used as a loading control. The
assay was performed on cells from three independent
biopsies.
Transcription factor assay for NF-κB (p65)
In order to detect specific NF-κB DNA binding activity
in nuclear extracts, the NF-κB (p65) Transcription Factor
Assay (Cayman, Estonia) was used according to the
protocol provided by the manufacturer. Briefly, a specific
double stranded DNA (dsDNA) sequence containing the
NF-κB response element was immobilized to the wells of
a 96 well plate. Nuclear extracts were prepared as
described above and added to the coated wells. NF-κB
contained in the added nuclear extract bound specifically
to the NF-κB response element and was detected by
addition of the provided specific primary antibody direc-
ted against NF-κB (p65). A secondary antibody conju-
gated with HRP was added, a colorimetric readout at
655 nm was performed and data was quantified as indi-
cated in the protocol. The assay was performed on cells
from two independent biopsies.
Western blot for MAP kinases (p38, ERK, JNK)
Whole cell extracts of untreated, IL-1β-treated and
IL-1β/curcumin-treated cells were prepared after 15 min
(using standard protocols) to investigate whether curcu-
min acts on typical MAP kinases. Protein content was
measured by Bradford assay and immunoblotting of whole
cell extracts was performed as described for p65, but
membranes were incubated with antibodies recognizing
Figure 1 Cytotoxicity of the curcuma DMSO extract (1a), curcuma ethanol extract (1b) and curcumin (1c) after 6, 18 and 30 hours. Data
was obtained by use of the MTT assay and is presented as Mean and SEM (n = 5). Asterisks indicate statistical significance (p < 0.05).
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(p42/44) or JNK (Cell Signaling, USA) before adding an
HRP-labeled rabbit secondary antibody and analyzing
chemiluminescence. Tubulin was used as a loading con-
trol. The assay was performed on samples from five in-
dependent experiments.Statistical analysis
All quantitative data (cytotoxicity, gene expression) was
statistically analyzed using a Mann Whitney U test on
the SPSS statistics software and differences were consid-
ered statistically significant at p < 0.05 (two-tailed).Results
Cytotoxicity of curcuma extracts and curcumin
Cytotoxicity of curcuma extracts (DMSO, ethanol) and
curcumin was determined after 6, 18 and 30 hours
(i.e. toxicity for short and long time points) using
the MTT assay. For the curcuma DMSO extract, cell
viability was constricted at concentrations of 500 μg/ml
(30 hours) and 1000 μg/ml (all time points) (Figure 1a).
A slight proliferative effect was observed for 100 μg/ml
(30 hours) and 250 μg/ml (18 hours). For the curcuma
ethanol extract, no cytotoxic effect could be observed at
any time point up to a concentration of 1000 μg/ml
(Figure 1b). For curcumin, cytotoxic effects could be
observed at concentrations of 50 μM (30 hours) and 100
μM (all time points) (Figure 1c).Changes in gene expression with IL-1β prestimulation
With IL-1β treatment, we could observe a significant in-
crease in the mRNA levels of all genes of interest at the
time of analysis (6 hours). Data for all genes is shown in
Table 3 as mean, SEM and p-value (data based on ana-
lysis of cells from 10 independent biopsies).Table 3 Effects of IL-1β stimulation on mRNA levels
of candidate genes after 6 hours
Gene Mean (Fold Change) SEM p-Value
IL-1β 246.34 48.12 <0.001
IL-6 2895.17 1571.28 <0.001
IL-8 241.89 56.71 <0.001
MMP1 166.05 31.06 <0.001
MMP3 260.58 70.75 <0.001
MMP13 119.06 29.49 <0.001
TNF-α 21.45 7.16 <0.001
TLR2 8.49 1.64 <0.001
Data was obtained by real-time RT-PCR (ΔΔct method) (n = 10).Changes in gene expression with curcuma DMSO and
ethanol extracts
As shown in the Supplementary Material (Additional file 1:
Figure S1 and Additional file 2: Figure S2), neither DMSO
nor EtOH at the used concentration (0.03%) influenced the
expression of the inflammatory and catabolic target genes.
Treatment with the curcuma DMSO extract resulted
in a significant inhibition of MMP1, MMP3 and MMP13
after 6 hours, relative to IL-1β prestimulated cells (which
are also supplemented with the respective volume of
DMSO). While no changes occurred in the expression of
IL-1β and IL-8, a significant inhibition of IL-6 was
observed. However, we noticed a strong induction of
TNF-α expression at this early time point. Expression of
TLR2 was significantly reduced. For all results see
Figure 2a as well as Additional file 3: Table S3 for sum-
marized values.
Compared to IL-1β prestimulated cells, treatment with
the curcuma EtOH extract did not cause any changes in
gene expression after 6 hours for MMP1 and MMP3
while slightly decreasing MMP13 expression. Expression
of IL-1β, IL-6 and IL-8 also remained unchanged, but
TNF-α expression was increased. TLR2 expression was
not influenced. For all results see Figure 2b as well as
Additional file 3: Table S3 for summarized values.
Analysis of the curcuma DMSO and EtOH extracts
(HPLC/MS)
Based on the above shown results, the DMSO fraction
seemed to contain one or more anti-catabolic and anti-
inflammatory substances. Taking the solubility of the
various components of curcuma as well as the literature-
based preselection of anti-inflammatory components of
curcuma into account, the curcuminoid curcumin was
chosen to be the most promising candidate substance
with biological activity. In order to proof that curcumin
was indeed present in the DMSO extract, HPLC/MS ana-
lysis was performed on the stock extracts (320 mg/ml).
The results showed that predominantly curcumin
(6.32 mg/ml) (Peak 1) was present in the extract (reten-
tion time 16.9 min, (M+H)+ at m/z 369.1), followed
by its precursors demethoxycurcumin (retention
time 15.4 min, (M+H)+ at m/z 339.1) (Peak 2) and
bisdemethoxycurcumin (retention time 13.7 min, (M+H)+
at m/z 309.1) (Peak 3) and other unidentified compounds
with little absorbance (Figure 3).
As curcumin is also soluble in EtOH, we performed a
sequential extraction process described under Materials
and Methods in order to aggregate curcumin in the
DMSO extract. Both, the sequential EtOH extract
(stock extract = 320 mg/ml) as well as the pure curcu-
min stock solution in DMSO (25 mM) were also mea-
sured by HPLC/MS. While the curcuma DMSO extract
contained 6.32 mg/ml of curcumin, the sequential
Figure 2 Effects of the curcuma DMSO extract (2a) and curcuma ethanol extract (2b) on mRNA levels of candidate genes after 6 hours,
indicated as fold change relative to IL-1β-treatment (IL-1β treated cells also contain 0.03% of DMSO or EtOH respectively). Data was
obtained by real-time RT-PCR (2-ΔΔCt method) and is presented as Mean and SEM (n = 5). Asterisks indicate statistical significance (p < 0.05). Each
gene was normalized to its respective IL-1β treatment (IL-1β + solvent), which was always set to 100% (only one exemplary control bar is shown).
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(Figure 4). Curcumin itself showed the highest value
and was in a similar range as the curcuma DMSO ex-
tract (8.80 mg/ml) (Figure 4).
Changes in gene expression with curcumin
Based on the above-mentioned findings, curcumin was
investigated at different concentrations (equalizing to theapproximate concentration of curcumin in the curcuma
extract) in more detail at the 6 hour time point. Treat-
ment with curcumin caused a significant reduction of
MMP1 (Figure 5a) and MMP3 (Figure 5b) at 10 μM and
20 μM. For MMP13, all concentrations of curcumin
caused a significant reduction (Figure 5c). Expression of
IL-1β (Figure 5d) and IL-6 (Figure 5e) was significantly
inhibited at both, 10 μM and 20 μM, while the lowest
Figure 3 Analysis of the composition of the curcuma DMSO
extract (black line) and the reference substance curcumin (grey
line, >94% purity with demethoxycurcumin and
bisdemethoxycurcumin as impurity) in DMSO by HPLC-DAD
(detection wavelength 425 nm). The three peaks were identified
as curcumin (1, retention time 16.9 min), demethoxycurcumin
(2, retention time 15.4 min) and bisdemethoxycurcumin (3, retention
time 13.7 min) by their (M+H)+ ions in the HPLC/MS analysis.
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pression was also decreased at 20 μM (Figure 5f ). In con-
trast, TNF-α expression was significantly increased at all
three curcumin concentrations, with the most prominent
effects at 20 μM (Figure 5g). Furthermore, TNF-α ex-
pression was also increased upon curcumin treatment
alone (i.e. if no IL-1β pretreatment was performed), while
all other target genes remained unaltered under these
conditions (data not shown). TLR2 expression was sig-
nificantly reduced with each concentration (Figure 5h).
For summarized values see Additional file 4: Table S4.Figure 4 HPLC/MS measurement of the curcumin concentration
in curcuma DMSO and curcuma EtOH stock extracts (320 mg/ml),
prepared by the described sequential extraction procedure.
In addition, the curcumin stock solution (25 mM; in DMSO) was
quantified.Analysis of NF-κB
Immunoblotting of p65 in nuclear extracts of untreated,
IL-1β-treated and IL-1β/curcumin-treated cells revealed
that IL-1β-treatment caused nuclear translocation of p65
after 60 min. However, compared to IL-1β stimulated
samples, curcumin treatment did not reduce levels of the
target protein in nuclear extracts (equal protein loading
was confirmed by PARP detection) (Figure 6a). Using the
NF-κB/p65 transcription factor assay, we provide further
evidence that IL-1β strongly induced NF-κB DNA bind-
ing (similar to the positive control = Pos Ctrl), while cur-
cumin was not able to reduce levels after IL-1β
stimulation (Figure 6b). Internal assay controls (i.e. com-
petition and non-specific binding control) ensured valid-
ity of the test.
Analysis of MAP kinases (p38, ERK, JNK)
Effects of curcumin on MAP kinase activity were investi-
gated by detection of levels of phosphorylated and
unphosporylated p38 (Figure 7a), ERK (Figure 7b) and
JNK (Figure 7c) using immunoblotting technique of
whole cell extracts. Results demonstrate that IL-1β treat-
ment increased levels of phosporylated p38, ERK and
JNK after 15 min, which is indicative of activation of
these MAP kinases. Treatment with curcumin reduced
activity of JNK compared to IL-1β treatment (i.e. reduced
levels of p-JNK), but further increased levels of p-ERK
and p-p38 compared to IL-1β treatment. Levels of
unphosporylated p38, ERK and JNK were similar in all
groups. Equal protein loading was confirmed by tubulin
detection.
Discussion
Changes in gene expression
Curcuma is not only an ancient spice, but also a trad-
itional remedy that has been used in Indian and Chinese
medicine to treat indigestion and many other medical
issues. Since the 1970s, the anti-inflammatory com-
pounds called curcuminoids were discovered in the spice,
with one (and probably the most important component)
being curucmin [22]. Because of its anti-inflammatory
properties, curcuma and its components (especially cur-
cumin) have been investigated in osteoarthritis and
rheumatoid arthritis during the past one to two decades,
while only one paper has been published on the effects of
curcumin on intervertebral disc cells so far [23].
Our results clearly show that the different curcuma
extracts influenced cellular behavior in a different
manner. While the curcuma EtOH extract (which con-
tained only little amounts of curcumin, as shown by
HPLC/MS) had no effect and was thus considered to be
not suitable for further investigations, the curcuma DMSO
extract as well as the DMSO-soluble compound curcumin
(which was shown to be present in the DMSO extract by
Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 Effects of curcumin (5, 10 or 20 μM) on mRNA levels of candidate genes after 6 hours, indicated as fold change relative to
IL-1β-treatment: MMP1 (5a); MMP3 (5b); MMP13 (5c); Interleukin-1β (5d); Interleukin-6 (5e); Interleukin-8 (5f); TNF-α (5g); TLR2 (5h)
(IL-1β treated cells also contain 0.03% of DMSO). Data was obtained by real-time RT-PCR (2-ΔΔCt method) and is presented as Mean and SEM
(n = 5). Asterisks indicate statistical significance (p < 0.05). Each gene was normalized to its respective IL-1β treatment (IL-1β + DMSO), which was
always set to 100% (only one exemplary control bar is shown).
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proinflammatory cytokines and matrix degrading enzymes
in our in vitro experiments. We were able to demonstrate
that the observed effect was not due to the biologic activity
of the solvents DMSO and EtOH (Additional file 1:
Figure S1 and Additional file 2: Figure S2), although the
anti-inflammatory properties of DMSO have most recently
been described in human intestinal cells [24].
Specifically, we could demonstrate a reduction in gene
expression of IL-6, MMP1, MMP3 and MMP13 when
treating IL-1β prestimulated cells with the curcuma DMSOFigure 6 Effects of curcumin on nuclear translocation of p65/NF-κB, m
60 min). 6a: Nuclear translocation of p65, measured by immunoblotting (n
PARP-1/2 is used as a loading control.
6b: NF-kB DNA binding activity, measured by NF-kB transcription factor ass
that different internal controls (positive control, competition control and unextract. Additionally, IL-1β and IL-8 were reduced by cur-
cumin treatment after 6 hours. As effects were comparable
between the curcuma DMSO extract and curcumin and as
curcumin was detected at high concentrations in the
DMSO extract by HPLC/MS, we hypothesize that the
major bioactive substance in curcuma DMSO extracts
acting on human intervertebral disc cells could be
curcumin. Due to the beneficial effects of curcumin, this
natural compound may be of benefit for patients with
inflammation-related back pain, with the potential mode of
application being intradiscal injection. Albeit curcumin iseasured by immunoblotting of p65 (n= 3, nuclear extracts,
=3, nuclear extracts, 60 min). One representative sample is shown and
ay (n=2, nuclear extracts, 60 min: without statistical evaluation). Note
specific binding control) were used to validate the test.
Figure 7 Effects of curcumin on MAP kinase activity, measured
by immunoblotting of p38/p-p38 (7a), ERK/p-ERK (7b) and JNK/
p-JNK (7c) (n = 5, whole cell extracts, 15 min). One representative
sample is shown and tubulin is used as a loading control.
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sumption, in vivo concentrations after injections should not
be a limiting factor.
The observed gene expression results are similar to
effects that were observed when treating other cell types
with curcumin, e.g. leading to a reduction in IL-1β [25-28],
IL-6 [25,28-30], IL-8 [25,31], MMP1 [32], MMP3 [26,32,33]
and MMP13 [32,34]. For IL-6, we observed a slight increase
at the lowest concentrations (1.5 fold), but a decrease at
higher concentrations. This may be due to biphasic effects
of curcumin that are based on its dual function to either
scavenge or produce reactive oxygen species [35]. However,
the biphasic nature of curcumin cannot explain that higher
concentrations of curcumin strongly stimulated expression
of TNF-α in human intervertebral disc cells (both, without
pretreatment as well as after IL-1β prestimulation), which
is different from what is described in the literature
[25,28,36]. Based on the current study we do not knowwhether this effect would also occur on the protein level
and in vivo. Therefore, further studies are thus required to
demonstrate safety and usefulness of curcumin in human
application.
So far, only one study investigated the effect of curcumin
on human intervertebral disc cells [23]. This study tested
curcumin for its effects on matrix protein gene expression,
but not on the expression of proinflammatory cytokines or
matrix degrading enzymes. Results of Yu et al.’s study indi-
cated that curcumin is also able to attenuate an IL-1
induced inhibition of SOX9 and collagen–II expression at
20 μg/ml (= 54.3 μM), which is higher than the concentra-
tions used in the present study and which was shown to be
a damaging concentration for other (disc-related) cell
types (e.g. C-28/I2= a chondrocyte cell line) [37]. Further-
more, it has to be noted that both, Yu’s as well as our study
were performed in a 2D culture system, which can cause
certain phenotypic changes of disc cells and may thus pos-
sibly influence cellular behavior to the tested treatment.
Pathway analysis
Curcumin seems to exhibit its anti-inflammatory and
anti-catabolic effects through versatile mechanisms. So
far, in different cell types, mainly inhibition of NF-κB,
MAP kinases and Toll-like receptors have been shown to
play a role [31,38-41].
NF-κB
Inhibition of the transcription factor NF-κB is the
best described mechanism of action of curcumin in
the literature [42]. A recent study in chondrocytes
showed that curcumin inhibits phosphorylation and
degradation of IκBα (= nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor, alpha)
and thus translocation of the p65 subunit of NF-κB
to the nucleus, indicating that inhibition of the
NF-κB pathway takes place at a step before IκBα
phosphorylation [41]. In intestinal epithelial cells,
curcumin seems to exert its effects by blocking a sig-
nal leading to IKK (= IκB kinase) activity [31]. How-
ever, in our experimental setting, curcumin did not
seem to reduce IL-1β induced nuclear translocation
of NF-κB/p65 or NF-κB DNA binding, which is in
contrast to data obtained by Yu et al. on interverte-
bral disc cells [23].
Toll-like receptors
We were able to demonstrate a down-regulation of TLR2
mRNA expression after treating IL-1β prestimulated IVD
cells with curcumin, which confirms findings in other
cell types such as monocytic THP-1 cells, HL-60 pro-
myelocytic leukemia cells and primary peripheral blood
polymorphonuclear neutrophils [38]. However, in a
leukemia cell line, Reuter et al. showed an increase in
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http://www.journal-inflammation.com/content/9/1/29TLR2 due to curcumin, although most inflammatory
mediators were simultaneously down-regulated in this
study [25]. There is also some evidence in the literature
that curcumin can reduce expression levels of TLR4
[29,43]. Based on how little is known about TLRs and
curcumin so far, more research is needed to establish a
causal relationship between therapeutic efficacy of curcu-
min and TLR2 activity.MAP kinases
The mitogen-activated protein (MAP) kinase signaling
pathways, including JNK, p38 and extracellular-signal
regulated kinase (ERK), play an important role in the
regulation of inflammatory responses [14]. As MAP
kinases are regulated by phosphorylation cascades, their
activity can be determined by detecting phosphorylation
levels. We found that curcumin was able to inhibit phos-
phorylation of JNK in IL-1β prestimulated IVD cells,
which is similar to primary chondrocytes [34,44]. Import-
antly, pharmacological inhibition of JNK (by SP600125)
has previously been shown to suppress MMP1, MMP3
and MMP13 mRNA expression in bovine and murine
IVD cells [45,46] (reviewed in [47]).
In contrast, phosphorylation of p38 and ERK was
induced upon curcumin treatment in IL-1β prestimu-
lated IVD cells as well as in curcumin-only treated IVD
cells, with a synergistic effect of IL-1β and curcumin
[48-50]. It may be possible that activation of p38 and
ERK led to the up-regulation of TNF-α expression
which was observed when IL-1β pretreated and un-
treated IVD cells were exposed to curcumin, but our
experimental design does not allow to establish a causal
relationship between MAP kinase activation and TNF-α
expression. Furthermore, activation of ERK and p38
does not only control inflammation, but also several
other cellular functions, such as cell cycle progression
for ERK (i.e. transition from the G1 to the S phase of
the cell cycle) [51] and cell growth and differentiation
for p38 [52], indicating that MAP kinase related cellular
control is of high complexity.Conclusion
In conclusion, the results of this study demonstrate that
curcumin may become an attractive alternative for the
treatment of discogenic back pain when envisaging an
intradiscal injection method, which will circumvent the
low bioavailability of curcumin. Although we were able
to show in a previous study (using a similar experimental
set-up) that another anti-inflammatory substance (resver-
atrol), caused pain-reducing effects in a rodent model of
radiculopathic pain in vivo [53], the analgetic effect of
curcumin first needs to be confirmed before clinical trials
are reasonable.Additional files
Additional file 1: Figure S1. Effects of 0.03% DMSO on mRNA levels of
candidate genes after 6 hours, indicated as fold change relative to
DMSO-free (i.e. untreated) controls (set to 1). Data was obtained by real-
time RT-PCR (2-ΔΔCt method) and is presented as Mean and SEM (n = 3).
Each gene was normalized to its respective DMSO-free control, which
was always set to 1 (only one exemplary untreated control bar is shown).
Additional file 2: Figure S2. Effects of 0.03% EtOH on mRNA levels of
candidate genes after 6 hours, indicated as fold change relative to EtOH-
free (i.e. untreated) controls (set to 1). Data was obtained by real-time RT-
PCR (2-ΔΔCt method) and is presented as Mean and SEM (n = 3). Each
gene was normalized to its respective EtOH-free control, which was
always set to 1 (only one exemplary untreated control bar is shown).
Additional file 3: Table S3. Summarized values of the graphical
illustration of the effects of the curcuma DMSO and EtOH extracts shown
in Figure 1. Quantitative values of the anti-catabolic and anti-
inflammatory effects of the curcuma DMSO and EtOH extracts on mRNA
levels of candidate genes after 6 hours (indicated as fold change relative
to IL-1β-prestimulation: 100%) are given only if a statistically significant
reduction occurred (p < 0.05). Note that IL-1β prestimulated cells also
contain 0.03% of DMSO or EtOH respectively. Data was obtained by real-
time RT-PCR (2-ΔΔCt method) and is presented as Mean and SEM (n = 5).
Additional file 4: Table S4. Summarized values of the graphical
illustration of the effects of curcumin shown in Figure 5. Quantitative
values of the anti-catabolic and anti-inflammatory effects of curcumin on
mRNA levels of candidate genes after 6 hours (indicated as fold change
relative to IL-1β-prestimulation: 100%) are given only if a statistically
significant reduction occurred (p < 0.05). Note that IL-1β prestimulated
cells also contain 0.03% of DMSO. Data was obtained by real-time RT-PCR
(2-ΔΔCt method) and is presented as Mean and SEM (n = 5).
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